Celcuity (CELC) Expected to Release Quarterly Earnings on Thursday

Key Points

• Celcuity is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting a loss of $1.50 per share and revenue of $1.60 million.
• The company missed consensus EPS estimates in its prior quarter, reporting a loss of $1.44 per share versus expectations of a $1.16 loss. Analysts project full-year EPS of negative $4.98.
• CELC shares opened at $69.13, well below their 52-week high of $151.02, while analyst sentiment remains generally positive: 13 Buy ratings support a “Moderate Buy” consensus and a $152.57 average price target.

Celcuity (NASDAQ:CELC - Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.50) per share and revenue of $1.60 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, analysts expect Celcuity to post ($4.98) EPS for the current fiscal year and ($2.53) EPS for the next fiscal year.

Celcuity Stock Performance

Shares of CELC stock opened at $69.13 on Friday. The stock's 50-day moving average price is $77.67 and its 200 day moving average price is $100.37. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a market capitalization of $3.38 billion, a PE ratio of -16.08 and a beta of 0.10. Celcuity has a 52-week low of $53.54 and a 52-week high of $151.02.

Analyst Ratings Changes

Several brokerages have weighed in on CELC. Wall Street Zen downgraded Celcuity from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Craig Hallum restated a "buy" rating and set a $178.00 price target on shares of Celcuity in a research note on Wednesday, July 15th. Cantor Fitzgerald began coverage on Celcuity in a report on Thursday, October 22nd. They set an "overweight" rating and a $140.00 price target for the company. Guggenheim lifted their price objective on shares of Celcuity from $165.00 to $175.00 and gave the company a "buy" rating in a research report on Monday, August 17th. Finally, Citizens Jmp reiterated a "market outperform" rating and issued a $177.00 price objective on shares of Celcuity in a research report on Monday, August 17th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $152.57.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company's CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.